• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Genelux Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    1/8/26 5:09:40 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNLX alert in real time by email
    false 0001231457 0001231457 2026-01-08 2026-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): January 8, 2026

     

    Genelux Corporation

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41599   77-0583529

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    2625 Townsgate Road, Suite 230    
    Westlake Village, California   91361
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (805) 267-9889

     

    Not Applicable

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, par value $0.001 per share   GNLX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 8.01 Other Events.

     

    Underwritten Public Offering

     

    On January 8, 2026, Genelux Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lucid Capital Markets, LLC ( the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten offering (the “Offering”) an aggregate of 6,666,667 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price to the public of $3.00 per share. All of the Shares are being sold by the Company.

     

    The gross proceeds to the Company from the offering will be approximately $20.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and assuming no exercise of the Underwriter’s option to purchase additional shares. The closing of the Offering is expected to occur on January 9, 2026, subject to the satisfaction of customary closing conditions.

     

    The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by such parties.

     

    The offering is being made pursuant to the Company’s effective shelf registration statement on Form S-3 and accompanying prospectus (File No. 333-276847), filed with the Securities and Exchange Commission (the “SEC”), and a prospectus supplement thereunder. A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this report, and the foregoing description of the terms of the Underwriting Agreement does not purport to be complete and are qualified in their entirety by reference to such exhibits. A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of the Shares in the Offering is attached as Exhibit 5.1 hereto.

     

    On January 7, 2026, the Company issued a press release announcing that the Company had commenced the Offering and on January 8, 2026, the Company issued a press release announcing that it had priced the Offering. Copies of these press releases are filed as Exhibits 99.1 and 99.2 hereto, respectively.

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act, and Section 21E of the Exchange Act. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements include statements about the Offering, such as the expected gross proceeds and anticipated closing date. These forward-looking statements are based on information currently available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including the uncertainties related to market conditions and the completion of the Offering on the anticipated terms or at all. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company’s business are described in additional detail in the Company’s filings with the SEC, including the Company’s latest Quarterly Report on Form 10-Q and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    1.1   Underwriting Agreement, by and between Genelux Corporation and Lucid Capital Markets, LLC, dated January 8, 2026
    5.1   Opinion of Cooley LLP
    23.1   Consent of Cooley LLP (included in Exhibit 5.1)
    99.1   Press Release, dated January 7, 2026
    99.2   Press Release, dated January 8, 2026
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Genelux Corporation
         
    Date: January 8, 2026 By: /s/ Thomas Zindrick, J.D.
       

    Thomas Zindrick, J.D.

    President and Chief Executive Officer

     

     

     

    Get the next $GNLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNLX

    DatePrice TargetRatingAnalyst
    10/21/2025$16.00Buy
    Lake Street
    10/29/2024$8.00Buy
    Guggenheim
    8/28/2024$10.00Buy
    ROTH MKM
    11/27/2023$35.00Buy
    H.C. Wainwright
    9/12/2023$40.00Buy
    Maxim Group
    2/15/2023$10.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $GNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Genelux with a new price target

    Lake Street initiated coverage of Genelux with a rating of Buy and set a new price target of $16.00

    10/21/25 7:59:44 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Genelux with a new price target

    Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00

    10/29/24 6:26:41 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Genelux with a new price target

    ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00

    8/28/24 7:46:18 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Tyree James L bought 6,250 shares, increasing direct ownership by 181% to 9,710 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:20 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Thomas John bought 2,500 shares, increasing direct ownership by 0.54% to 465,960 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:16 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smither John W bought 6,250 shares, increasing direct ownership by 90% to 13,170 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:18 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    SEC Filings

    View All

    Genelux Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - GENELUX Corp (0001231457) (Filer)

    1/8/26 5:09:40 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Genelux Corporation

    424B5 - GENELUX Corp (0001231457) (Filer)

    1/8/26 5:05:54 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Genelux Corporation

    424B5 - GENELUX Corp (0001231457) (Filer)

    1/7/26 4:48:36 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

    WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ("Genelux") (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of the shares in the offering are to be sold by Genelux. The gross proceeds to Genelux from the offering are expected to be approximately $20.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. In addition, Genelux has granted the underwriter a 30-day option to purchase up to an additional 1,000,000 shares of its common s

    1/8/26 9:13:39 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Announces Proposed Public Offering of Common Stock

    WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ("Genelux") (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a proposed underwritten public offering of its common stock. In addition, Genelux expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the proposed offering. All shares are being offered by Genelux. The proposed offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of

    1/7/26 4:01:00 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials

    -- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing – -- In platinum-relapsed or platinum-refractory advanced SCLC, two of three partial responses (PRs) occurred in the highest dose cohort tested as of the data review cutoff date (tumor shrinkage of ~55% and ~85%), with three PRs out of nine subjects (33%) across all dose cohorts; observed durable response signals and treatment tolerability (Phase 1b/2 SCLC) -- -- In advanced or metastatic recurrent NSCLC, observed anti-tumor activity in initial dose cohort and Olvi-Vec generally wel

    1/5/26 8:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Litten Jason

    4 - GENELUX Corp (0001231457) (Issuer)

    1/7/26 5:32:02 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Litten Jason

    3 - GENELUX Corp (0001231457) (Issuer)

    1/7/26 5:30:31 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Zindrick Thomas sold $66,370 worth of shares (17,182 units at $3.86), decreasing direct ownership by 3% to 538,431 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    12/11/25 8:50:01 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Leadership Updates

    Live Leadership Updates

    View All

    Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. "We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes," said Thomas Zindrick, President, CEO, and Chairman of the Board. "He brings extensive experience in oncology drug development of innovati

    1/2/26 8:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

    WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum continued to build across the Company, as it looks forward to a series of key clinical readouts over the next year. These readouts are intended to further demonstrate the ability of Olvi-Vec to resensitize tumors to frontline platinum-based regimens. Genelux continues to advance Olvi-Vec toward potential registration in platinum-resistant/refractory ovarian cancer (PRROC) with topline data expected in the first half of 2026. Earlier this

    8/7/25 4:20:00 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

    WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025. "We are delighted to welcome Eric to the executive team," said Thomas Zindrick, President, CEO, and Chairman of the Board. "Eric brings a powerful blend of legal expertise, global business development savvy, and a strategic understanding of the biotechnology ecosystem. His proven ability to lead high-impact transactions, build trusted partnerships, and navigate complex regulatory

    7/7/25 7:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

    Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

    6/10/24 12:35:45 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Genelux Corporation

    SC 13G - GENELUX Corp (0001231457) (Subject)

    10/25/24 9:45:20 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Genelux Corporation

    SC 13G/A - GENELUX Corp (0001231457) (Subject)

    10/22/24 4:12:19 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genelux Corporation

    SC 13G - GENELUX Corp (0001231457) (Subject)

    2/2/24 4:06:25 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care